The Investigation Of Relationship Between Therapeutic Effect And Prognosis And Changes Of Peripheral Blood Vascular Endothelial Growth Factor And Metallothionein In Patients With Advanced Lung Cancer

Objective:To investigate the relationship between the combined detection of Peripheral Blood vascular endothelial growth factor (VEGF), metallothionein(MT) and pathological type, lymph node metastasis, efficacy and prognosis and other factors in Patients with advanced lung cancer. Methods:The study were divided into lung cancer group (33 patients with advanced lung cancer patients) and control group (30 healthy people).The serum VEGF and MT levels were measured by ABC-ELISA double antibody sandwich method in the two groups. Peripheral blood mononuclear cells expression of VEGF mRNA and MT mRNA were measured by Reverse transcription polymerase chain reaction (RT-PCR). Results:Serum VEGF and MT normal expression level were (174.3±60.1) pg/ml and (5.7±2.8) ng/ml, VEGF and MT expression level in Lung cancer patients before treatment were (401.2±142.4) pg/ml and (13.9±6.0) ng/ml, Serum VEGF and MT expression level in patients with lung cancers before chemotherapy were significantly higher than normal group (P<0.01). Peripheral blood VEGF mRNA and MT mRNA in normal group were (48.8±24.1) and (95.0±30.3) VEGF mRNA and MT mRNA in Lung cancer patients before chemotherapy expression level were (209.6±90.3) and (184.2±103.2), MT mRNA and VEGF mRNA in Lung cancer patients before chemotherapy was significantly higher than normal group. Serum VEGF levels in lung cancer patients after chemotherapy were Less than the before (P <0.05). However, VEGF mRNA in Peripheral Blood before and after the chemotherapy of advanced lung cancer have no difference (P> 0.05); MT protein and mRNA in peripheral blood before and after the chemotherapy of advanced lung cancer have no differences (P> 0.05).VEGF and MT have no correlation with gender, pathological type, lymph node metastasis and efficacy, the differences have not statistically significant (P> 0.05).The positive rates of VEGF and MT in lung cancer patients were 78.8% and 63.6%.There were no correlation between the measured value of serum VEGF and MT. Conclusion: Combined detection of serum VEGF and MT can improve the positive rate, while there were no correlation between the two indexes. VEGF and MT have no correlation with gender, pathological type, lymph node metastasis , efficacy and prognosis in advanced lung cancer.